HIPEC ensures 1 year longer survival in ovarian cancer


A team of researchers from the Netherlands Cancer Institute published an important article in Lancet Oncology. The article shows that women with ovarian cancer who have received a treatment called heated chemotherapy (hyperthermic intraperitoneal chemotherapy; HIPEC) still benefit from this therapy after ten years. This new analysis of the OVHIPEC-1 study confirms that HIPEC treatment delays the recurrence of ovarian cancer by four months and extends life by a year. This phase 3 study was initiated and conducted in six Dutch centers, and headed by principal investigators Willemien van Driel and Gabe Sonke from the Netherlands Cancer Institute.

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.